Scientific publications
GeNeuro’s science is based on more than 25 years of research, performed internally and in collaboration with renowned academic groups.
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
MS Journal, July 9, 2021
https://geneuro.ch/data/news/MSJ-July-21-Efficacy-and-safety-of-temelimab-in-multiple-sclerosis.pdf
Temelimab for prevention of neurodegeneration: preclinical safety profile and design of the ProTEct-MS (temelimab following rituximab in RMS) study
MS Virtual 2020 – 8th Joint ACTRIMS-ECTRIMS Meeting, September 11-13
pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis
PNAS, July 23, 2019
A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env
Clinical Therapeutics, July 13, 2019
https://www.clinicaltherapeutics.com/article/S0149-2918(19)30296-6/pdf
ECTRIMS 2109 – Neuroprotective effects of temelimab in relapsing-remitting MS patients extend to 96 weeks
Phase IIb safety and efficacy data on temelimab at week 96 from the ANGEL-MS study
Neural Cell Responses Upon Exposure to Human Endogenous Retroviruses
Frontiers in Genetics, July 11, 2019
https://www.frontiersin.org/articles/10.3389/fgene.2019.00655/full